Cullinan Therapeutics annual depreciation and amortization
2020
2021
2022
2023
2024
2025
Cullinan Therapeutics Depreciation & Amortization Growth & History (CGEM)
Cullinan Therapeutics's depreciation and amortization was $311,000 for fiscal 2025.
View full Cullinan Therapeutics company overviewCullinan Therapeutics annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $311,000 | $5,000 | +1.63% |
| 2024 | 2024-12-31 | $306,000 | −$4,000 | −1.29% |
| 2023 | 2023-12-31 | $310,000 | $217,000 | +233.33% |
| 2022 | 2022-12-31 | $93,000 | $40,000 | +75.47% |
| 2021 | 2021-12-31 | $53,000 | −$9,000 | −14.52% |
| 2020 | 2020-12-31 | $62,000 | — | — |
Cullinan Therapeutics quarterly depreciation and amortization
Q1.20
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q1.22
Q2.22
Q3.22
Q1.23
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $79,000 | $2,000 | +2.60% |
| Q1 2026 | 2026-03-31 | $79,000 | $3,000 | +3.95% |
| Q4 2025 | 2025-12-31 | $79,000 | — | — |
| Q3 2025 | 2025-09-30 | $79,000 | $3,000 | +3.95% |
| Q2 2025 | 2025-06-30 | $77,000 | $0 | 0.00% |
| Q1 2025 | 2025-03-31 | $76,000 | $0 | 0.00% |
| Q3 2024 | 2024-09-30 | $76,000 | −$4,000 | −5.00% |
| Q2 2024 | 2024-06-30 | $77,000 | −$4,000 | −4.94% |
| Q1 2024 | 2024-03-31 | $76,000 | $4,000 | +5.56% |
| Q3 2023 | 2023-09-30 | $80,000 | $71,000 | +788.89% |
| Q2 2023 | 2023-06-30 | $81,000 | $69,000 | +575.00% |
| Q1 2023 | 2023-03-31 | $72,000 | $59,000 | +453.85% |
| Q3 2022 | 2022-09-30 | $9,000 | −$4,000 | −30.77% |
| Q2 2022 | 2022-06-30 | $12,000 | −$1,000 | −7.69% |
| Q1 2022 | 2022-03-31 | $13,000 | −$2,000 | −13.33% |
| Q3 2021 | 2021-09-30 | $13,000 | −$2,000 | −13.33% |
| Q2 2021 | 2021-06-30 | $13,000 | −$3,000 | −18.75% |
| Q1 2021 | 2021-03-31 | $15,000 | −$1,000 | −6.25% |
| Q3 2020 | 2020-09-30 | $15,000 | — | — |
| Q2 2020 | 2020-06-30 | $16,000 | — | — |
| Q1 2020 | 2020-03-31 | $16,000 | — | — |
Cullinan Therapeutics depreciation and amortization trends
Over the last five fiscal years, Cullinan Therapeutics's depreciation and amortization increased from $62,000 to $311,000, a change of $249,000. The latest reported quarter, Q2 2026, shows $79,000.
About the metric
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Calculation and source
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Cullinan Therapeutics source filings ↗